Business
Acurx is a clinical-stage biopharmaceutical company developing a new class of antibiotics for priority pathogens and antimicrobial resistance.
Acurx cut losses and strengthened equity, but ibezapolstat still needs Phase 3 funding and a going-concern issue remains.
The read at a glance✓ Audited against SEC data
- Business mix — Ibezapolstat antibiotic platformNote
- Revenue — No revenue in local bundleNote
- Profitability — Net loss improved to $8.0MOK
- Cash burn — Cash from operations improved to -$6.8MOK
- Balance sheet — Equity rose to $5.3MOK
- Insiders — 0 buys / 0 sellsNote
- Accounting — Going-concern warningWatch
Latest filings
- 10-Q · Quarterly report2026-08-13
- 10-Q · Quarterly report2026-05-11
- 8-K · Company announcement2026-04-16
- 10-K · Annual report2026-03-12
- 8-K · Company announcement2026-03-09
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Acurx Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.